# antibodies .- online.com







## anti-BRE antibody (AA 94-383) (HRP)



| ( ) | 1/0 | r\ /1 | 014 |   |
|-----|-----|-------|-----|---|
| ( ) | ve  | I V I | -v  | V |
|     |     |       |     |   |

| Quantity:            | 100 μg                                 |
|----------------------|--|
| Target:              | BRE                                    |
| Binding Specificity: | AA 94-383                              |
| Reactivity:          | Human                                  |
| Host:                | Rabbit                                 |
| Clonality:           | Polyclonal                             |
| Conjugate:           | This BRE antibody is conjugated to HRP |
| Application:         | ELISA                                  |

#### **Product Details**

| Immunogen:        | Recombinant Human BRISC and BRCA1-A complex member 2 protein (94-383AA) |  |
|-------------------|---|--|
| Isotype:          | IgG   |  |
| Cross-Reactivity: | Human   |  |
| Purification:     | >95%, Protein G purified  |  |

### Target Details

| Target:           | BRE   |
|-------------------|---|
| Alternative Name: | BABAM2 (BRE Products)   |
| Background:       | Background: Component of the BRCA1-A complex, a complex that specifically recognizes \'Lys- |
|                   | 63\'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the |

BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes \'Lys-63\'linked ubiquitin on histones H2A and H2AX (PubMed:17525341, PubMed:19261746, PubMed:19261749, PubMed:19261748). In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer (PubMed:21282113, PubMed:19261748). Component of the BRISC complex, a multiprotein complex that specifically cleaves \'Lys-63\'-linked ubiquitin in various substrates (PubMed:19214193, PubMed:24075985, PubMed:25283148, PubMed:26195665). Within the BRISC complex, acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity (PubMed:21282113). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). The BRISC complex plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1, deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A, however these effects may be indirect (PubMed:15465831).

Aliases: 6030405P19Rik antibody, Al429776 antibody, B830038C02Rik antibody, Brain and reproductive organ expressed (TNFRSF1A modulator) antibody, brain and reproductive organ expressed protein antibody, Brain and reproductive organ-expressed protein antibody, BRCA1 A complex subunit BRE antibody, BRCA1-A complex subunit BRE antibody, BRCA1/BRCA2 containing complex subunit 4 antibody, BRCA1/BRCA2 containing complex subunit 45 antibody, BRCA1/BRCA2-containing complex subunit 45 antibody, BRCA1/BRCA2-containing complex subunit 45 antibody, BRCC4 antibody, BRCC45 antibody, BRE\_HUMAN antibody

UniProt:

Q9NXR7

Pathways:

Positive Regulation of Response to DNA Damage Stimulus

#### **Application Details**

Application Notes:

Optimal working dilution should be determined by the investigator.

### **Application Details**

| Restrictions:      | For Research Use only  |  |
|--------------------|--|--|
| Handling           |  |  |
|                    |  |  |
| Format:            | Liquid   |  |
| Buffer:            | Preservative: 0.03 % Proclin 300   |  |
|                    | Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4                                     |  |
| Preservative:      | ProClin  |  |
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be |  |
|                    | handled by trained staff only.   |  |
| Storage:           | -20 °C,-80 °C  |  |
| Storage Comment:   | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.                      |  |